2026 Q2 -tulosraportti
16 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
3,95%Tuotto/v
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·3 t sittenDenmark stifles investments with high taxes and political passivity.. Why should international companies choose Denmark when we insist on making ourselves more expensive than the competitors? Eli Lilly invests massively in Ireland, where the corporate tax is 12.5 percent, while Danish companies like Novo Nordisk are taxed with three layers - first Novo Nordisk with 22 percent in corporate tax, then the shareholders with dividend tax 27-42 percent, and finally capital gains tax on shares of 27-42 percent.. It's not hard to understand where capital flows when conditions are better elsewhere. Lower that corporate tax to 15 percent. And the financing? It actually exists. Denmark has large socially created tax-free assets, which politicians for years have been too afraid to touch, where values only increase as long as no one changes an insane housing system.. Many live in the same residential areas and the same associations as the voters who benefit from the current rules. The result is a system where ordinary wage earners and productive companies are squeezed, while housing assets and local special interests are spared.. Denmark does not have a growth problem, we have a political courage problem. It is politically much more difficult to touch that than to impose more burdens on companies and ordinary wage earners. These are the reasons why reforms often stall. A sign that democracy is under pressure if major economic decisions are shaped by special interests rather than the broad societal interest. It is dangerous because the strength of democracy is precisely built on people believing that the rules apply roughly to everyone. Democracy is not about elections. It is also about the ability to make necessary decisions before problems grow larger in Denmark
It's not that simple Only trading in Ireland is taxed at 12.5% Otherwise it's 25 % DK has in several areas, e.g. R&D, much better tax deductions than Ireland There are many differences that give an advantage to either ir or dk It is very extensive to compare, it can only be done with actual figures. I suggest you ask AI with concrete examples before you use info- ·5 t sitten · MuokattuNow one can analyze as one wishes. Here's what I think.. The big investors regain interest in Novo at the Q1 report, where the first evidence emerges that Novo again has control of the business. The share price is traded back to 270 where there is massive buying. On the way to Q2, the share price rose 40 percent, and ran far too fast, as the strong hands were not at all finished with buying. 338 had become too high, but there was nothing but good news, so what do you do then? A failed "anonymous" study was therefore welcome and could take the first 10 percent, followed by a Q2 report that once again proved that Novo is on its way back. Under normal circumstances, the share price would have soared on the upward adjustment we saw. But here we had to go back to page 19 again, to find a reason for a 6 percent fall. Then they were given three weeks of bad sentiment, where the strong hands could again fill up at prices of 289-290 👍 The point is, the strong hands have long known that Novo is recovering, and is coming back in, but the share price must not get too high too quickly! - therefore we see so much at the moment that seems illogical where the share price experiences setbacks, under completely 'unreasonable' circumstances. Interpret it positively, it's a big signal to us that THEY are on their way back👍👍 just my very own interpretation 😊
The "strong hands" have no sentimental thoughts. Just as little as they have thoughts of revenge. The only thing that matters is profit! What they do have a lot of, however, is knowledge, analysis tools, algorithmic trading tools, the best educated, and the strongest talents. They use this to make as much money as possible by placing money in the right place at the right time. If one disregards dedicated short-sellers, there is vanishingly little gambling, conspiracy, and trickery. (There will always be some insider trading.) The "strong hands" can influence price development in relatively large and solid knowledge, but to manipulate the price in Novo, several consortia must join forces. (That only happens in movies. Keeping such things hidden is almost impossible.) The best thing is to familiarize oneself with the company and try to understand as best as possible how the development appears to be - right now. Then one can form thoughts about how it will go tomorrow. The most important thing to know about the "strong hands" is that they naturally make a lot of money on both Novo and LLY. The "strong hands" are your best friends if you just understand (as much as possible) how they think. Follow the money = follow the "strong hands". 
6 t sittenUPDATE: Aug. 21, 2026 After a one-week hiccup, Novo Nordisk’s Wegovy pill regained its momentum last week with its largest prescription rate since it was launched in January. There were more than 176,000 prescriptions for the pill in the period, according to data gathered by IQVIA and cited in a note by Citi. The oral treatment now accounts for 35% of total Wegovy prescriptions, which is up from 33% the previous week, analysts from Citi said in their weekly update to investors. Meanwhile, Eli Lilly’s oral GLP-1 Foundayo, which had been on a steady five-week climb, backtracked, with a drop off from 38,928 prescriptions in the prior period to 36,620 in the latest week. The movements for the two oral treatments contributed to overall market share adjustments for the companies' diabetes and obesity medicines. While Lilly made a 0.1% gain to 56.7%, Novo increased its market share by 0.3% to 37.1%.
·7 t sitten · MuokattuBeautiful! Pure thrashing for Foundayo… Today's IQVIA figures which are more comprehensive than Symphony Health data and therefore more indicative. It is the most important figure of the two. Oral Wegovy rises 8.0% to 176,373. Last week 163,329. Lilly’s Foundayo fell 5.9% to 36,619 after 38,928 last week. https://x.com/investseekers/status/2090794933468713021?s=20
That Foundayo is falling back is significant! Exciting to see how Fierce Pharma interprets the numbers when they update the chart - they usually succeed in talking Novo down and Eli up😀
·7 t sittenPrescription count - which was good, was then rewarded here at the end. But seems a bit peculiar at this late stage. Pharma has risen nicely but why? Is the Iran war active again. Then there is room for the weekend team - for the next couple of days. - Around the clock.
if novo is right in their strategy then I think the stock will cost 500 kr. in 2 years, but lots of bumps on the road, right now it is a really good dividend stock..
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q2 -tulosraportti
16 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
3,95%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·3 t sittenDenmark stifles investments with high taxes and political passivity.. Why should international companies choose Denmark when we insist on making ourselves more expensive than the competitors? Eli Lilly invests massively in Ireland, where the corporate tax is 12.5 percent, while Danish companies like Novo Nordisk are taxed with three layers - first Novo Nordisk with 22 percent in corporate tax, then the shareholders with dividend tax 27-42 percent, and finally capital gains tax on shares of 27-42 percent.. It's not hard to understand where capital flows when conditions are better elsewhere. Lower that corporate tax to 15 percent. And the financing? It actually exists. Denmark has large socially created tax-free assets, which politicians for years have been too afraid to touch, where values only increase as long as no one changes an insane housing system.. Many live in the same residential areas and the same associations as the voters who benefit from the current rules. The result is a system where ordinary wage earners and productive companies are squeezed, while housing assets and local special interests are spared.. Denmark does not have a growth problem, we have a political courage problem. It is politically much more difficult to touch that than to impose more burdens on companies and ordinary wage earners. These are the reasons why reforms often stall. A sign that democracy is under pressure if major economic decisions are shaped by special interests rather than the broad societal interest. It is dangerous because the strength of democracy is precisely built on people believing that the rules apply roughly to everyone. Democracy is not about elections. It is also about the ability to make necessary decisions before problems grow larger in DenmarkIt's not that simple Only trading in Ireland is taxed at 12.5% Otherwise it's 25 % DK has in several areas, e.g. R&D, much better tax deductions than Ireland There are many differences that give an advantage to either ir or dk It is very extensive to compare, it can only be done with actual figures. I suggest you ask AI with concrete examples before you use info
- ·5 t sitten · MuokattuNow one can analyze as one wishes. Here's what I think.. The big investors regain interest in Novo at the Q1 report, where the first evidence emerges that Novo again has control of the business. The share price is traded back to 270 where there is massive buying. On the way to Q2, the share price rose 40 percent, and ran far too fast, as the strong hands were not at all finished with buying. 338 had become too high, but there was nothing but good news, so what do you do then? A failed "anonymous" study was therefore welcome and could take the first 10 percent, followed by a Q2 report that once again proved that Novo is on its way back. Under normal circumstances, the share price would have soared on the upward adjustment we saw. But here we had to go back to page 19 again, to find a reason for a 6 percent fall. Then they were given three weeks of bad sentiment, where the strong hands could again fill up at prices of 289-290 👍 The point is, the strong hands have long known that Novo is recovering, and is coming back in, but the share price must not get too high too quickly! - therefore we see so much at the moment that seems illogical where the share price experiences setbacks, under completely 'unreasonable' circumstances. Interpret it positively, it's a big signal to us that THEY are on their way back👍👍 just my very own interpretation 😊The "strong hands" have no sentimental thoughts. Just as little as they have thoughts of revenge. The only thing that matters is profit! What they do have a lot of, however, is knowledge, analysis tools, algorithmic trading tools, the best educated, and the strongest talents. They use this to make as much money as possible by placing money in the right place at the right time. If one disregards dedicated short-sellers, there is vanishingly little gambling, conspiracy, and trickery. (There will always be some insider trading.) The "strong hands" can influence price development in relatively large and solid knowledge, but to manipulate the price in Novo, several consortia must join forces. (That only happens in movies. Keeping such things hidden is almost impossible.) The best thing is to familiarize oneself with the company and try to understand as best as possible how the development appears to be - right now. Then one can form thoughts about how it will go tomorrow. The most important thing to know about the "strong hands" is that they naturally make a lot of money on both Novo and LLY. The "strong hands" are your best friends if you just understand (as much as possible) how they think. Follow the money = follow the "strong hands".
- 6 t sittenUPDATE: Aug. 21, 2026 After a one-week hiccup, Novo Nordisk’s Wegovy pill regained its momentum last week with its largest prescription rate since it was launched in January. There were more than 176,000 prescriptions for the pill in the period, according to data gathered by IQVIA and cited in a note by Citi. The oral treatment now accounts for 35% of total Wegovy prescriptions, which is up from 33% the previous week, analysts from Citi said in their weekly update to investors. Meanwhile, Eli Lilly’s oral GLP-1 Foundayo, which had been on a steady five-week climb, backtracked, with a drop off from 38,928 prescriptions in the prior period to 36,620 in the latest week. The movements for the two oral treatments contributed to overall market share adjustments for the companies' diabetes and obesity medicines. While Lilly made a 0.1% gain to 56.7%, Novo increased its market share by 0.3% to 37.1%.
- ·7 t sitten · MuokattuBeautiful! Pure thrashing for Foundayo… Today's IQVIA figures which are more comprehensive than Symphony Health data and therefore more indicative. It is the most important figure of the two. Oral Wegovy rises 8.0% to 176,373. Last week 163,329. Lilly’s Foundayo fell 5.9% to 36,619 after 38,928 last week. https://x.com/investseekers/status/2090794933468713021?s=20That Foundayo is falling back is significant! Exciting to see how Fierce Pharma interprets the numbers when they update the chart - they usually succeed in talking Novo down and Eli up😀
- ·7 t sittenPrescription count - which was good, was then rewarded here at the end. But seems a bit peculiar at this late stage. Pharma has risen nicely but why? Is the Iran war active again. Then there is room for the weekend team - for the next couple of days. - Around the clock.if novo is right in their strategy then I think the stock will cost 500 kr. in 2 years, but lots of bumps on the road, right now it is a really good dividend stock..
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
2026 Q2 -tulosraportti
16 päivää sitten
‧1 t 2 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
3,75 DKK/osake
Viimeisin osinko
3,95%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·3 t sittenDenmark stifles investments with high taxes and political passivity.. Why should international companies choose Denmark when we insist on making ourselves more expensive than the competitors? Eli Lilly invests massively in Ireland, where the corporate tax is 12.5 percent, while Danish companies like Novo Nordisk are taxed with three layers - first Novo Nordisk with 22 percent in corporate tax, then the shareholders with dividend tax 27-42 percent, and finally capital gains tax on shares of 27-42 percent.. It's not hard to understand where capital flows when conditions are better elsewhere. Lower that corporate tax to 15 percent. And the financing? It actually exists. Denmark has large socially created tax-free assets, which politicians for years have been too afraid to touch, where values only increase as long as no one changes an insane housing system.. Many live in the same residential areas and the same associations as the voters who benefit from the current rules. The result is a system where ordinary wage earners and productive companies are squeezed, while housing assets and local special interests are spared.. Denmark does not have a growth problem, we have a political courage problem. It is politically much more difficult to touch that than to impose more burdens on companies and ordinary wage earners. These are the reasons why reforms often stall. A sign that democracy is under pressure if major economic decisions are shaped by special interests rather than the broad societal interest. It is dangerous because the strength of democracy is precisely built on people believing that the rules apply roughly to everyone. Democracy is not about elections. It is also about the ability to make necessary decisions before problems grow larger in DenmarkIt's not that simple Only trading in Ireland is taxed at 12.5% Otherwise it's 25 % DK has in several areas, e.g. R&D, much better tax deductions than Ireland There are many differences that give an advantage to either ir or dk It is very extensive to compare, it can only be done with actual figures. I suggest you ask AI with concrete examples before you use info
- ·5 t sitten · MuokattuNow one can analyze as one wishes. Here's what I think.. The big investors regain interest in Novo at the Q1 report, where the first evidence emerges that Novo again has control of the business. The share price is traded back to 270 where there is massive buying. On the way to Q2, the share price rose 40 percent, and ran far too fast, as the strong hands were not at all finished with buying. 338 had become too high, but there was nothing but good news, so what do you do then? A failed "anonymous" study was therefore welcome and could take the first 10 percent, followed by a Q2 report that once again proved that Novo is on its way back. Under normal circumstances, the share price would have soared on the upward adjustment we saw. But here we had to go back to page 19 again, to find a reason for a 6 percent fall. Then they were given three weeks of bad sentiment, where the strong hands could again fill up at prices of 289-290 👍 The point is, the strong hands have long known that Novo is recovering, and is coming back in, but the share price must not get too high too quickly! - therefore we see so much at the moment that seems illogical where the share price experiences setbacks, under completely 'unreasonable' circumstances. Interpret it positively, it's a big signal to us that THEY are on their way back👍👍 just my very own interpretation 😊The "strong hands" have no sentimental thoughts. Just as little as they have thoughts of revenge. The only thing that matters is profit! What they do have a lot of, however, is knowledge, analysis tools, algorithmic trading tools, the best educated, and the strongest talents. They use this to make as much money as possible by placing money in the right place at the right time. If one disregards dedicated short-sellers, there is vanishingly little gambling, conspiracy, and trickery. (There will always be some insider trading.) The "strong hands" can influence price development in relatively large and solid knowledge, but to manipulate the price in Novo, several consortia must join forces. (That only happens in movies. Keeping such things hidden is almost impossible.) The best thing is to familiarize oneself with the company and try to understand as best as possible how the development appears to be - right now. Then one can form thoughts about how it will go tomorrow. The most important thing to know about the "strong hands" is that they naturally make a lot of money on both Novo and LLY. The "strong hands" are your best friends if you just understand (as much as possible) how they think. Follow the money = follow the "strong hands".
- 6 t sittenUPDATE: Aug. 21, 2026 After a one-week hiccup, Novo Nordisk’s Wegovy pill regained its momentum last week with its largest prescription rate since it was launched in January. There were more than 176,000 prescriptions for the pill in the period, according to data gathered by IQVIA and cited in a note by Citi. The oral treatment now accounts for 35% of total Wegovy prescriptions, which is up from 33% the previous week, analysts from Citi said in their weekly update to investors. Meanwhile, Eli Lilly’s oral GLP-1 Foundayo, which had been on a steady five-week climb, backtracked, with a drop off from 38,928 prescriptions in the prior period to 36,620 in the latest week. The movements for the two oral treatments contributed to overall market share adjustments for the companies' diabetes and obesity medicines. While Lilly made a 0.1% gain to 56.7%, Novo increased its market share by 0.3% to 37.1%.
- ·7 t sitten · MuokattuBeautiful! Pure thrashing for Foundayo… Today's IQVIA figures which are more comprehensive than Symphony Health data and therefore more indicative. It is the most important figure of the two. Oral Wegovy rises 8.0% to 176,373. Last week 163,329. Lilly’s Foundayo fell 5.9% to 36,619 after 38,928 last week. https://x.com/investseekers/status/2090794933468713021?s=20That Foundayo is falling back is significant! Exciting to see how Fierce Pharma interprets the numbers when they update the chart - they usually succeed in talking Novo down and Eli up😀
- ·7 t sittenPrescription count - which was good, was then rewarded here at the end. But seems a bit peculiar at this late stage. Pharma has risen nicely but why? Is the Iran war active again. Then there is room for the weekend team - for the next couple of days. - Around the clock.if novo is right in their strategy then I think the stock will cost 500 kr. in 2 years, but lots of bumps on the road, right now it is a really good dividend stock..
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt